UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ (Exact Name of Registrant as Specified in its Charter) Securities registered pursuant to Section 12(b) of the Act: (State or Ot ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2020 Earnings Conference Call April 27, 2020 8:00 AM ET Company Participants Dr. Kimberly Lee - Head, IR and Corporate Strategy Lonnel Coats - President and CEO Alex Santini - EVP and Chief Commercial Officer Dr. Pablo Lapuerta - EVP and Chief Medical Officer Dr. Praveen Tyle - EVP, Research and Development Jeff Wade - EVP, Corporate and Administrative Affairs and CFO Conference Call Participants Yigal Nochomovitz - Citigroup Liana Moussatos - Wedbush Securitie ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 76-0 ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2019 Results Conference Call March 12, 2020 8:00 AM ET Company Participants Dr. Kimberly Lee - Head, IR and Corporate Strategy Lonnel Coats - President and CEO Alex Santini - EVP and Chief Commercial Officer Dr. Pablo Lapuerta - EVP and Chief Medical Officer Dr. Praveen Tyle - EVP, Research and Development Jeff Wade - EVP, Corporate and Administrative Affairs and CFO Conference Call Participants Samantha Semenkow - Citi Kambiz Yazdi - Wedbush Securities Stephen ...

Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) Q3 2019 Earnings Conference Call November 7, 2019 8:00 AM ET Company Participants Lonnel Coats - President and Chief Executive Officer Alex Santini - Executive Vice President and Chief Commercial Officer Dr. Pablo Lapuerta - Executive Vice President and Chief Medical Officer Dr. Praveen Tyle - Executive Vice President, Research and Development Jeff Wade - Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer Dr. Kimberly Lee - H ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 or q TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (Sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 or q TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (State or ...

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Q2 2019 Results Conference Call August 1, 2019 9:00 AM ET Company Participants Kimberly Lee - Head of Investor Relations and Corporate Strategy Lonnel Coats - President and Chief Executive Officer Alex Santini - Executive Vice President and Chief Commercial Officer Dr. Pablo Lapuerta - Executive Vice President and Chief Medical Officer Dr. Praveen Tyle - Executive Vice President of Research and Development Jeff Wade - Executive Vice President and Chief Financial Of ...

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 or q TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (State o ...